The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation

Area of Science:

• Immunology
• Pharmacology
• Oncology

Background:

• The mammalian target of rapamycin (mTOR) inhibitor rapamycin has been used in organ transplantation for two decades.
• Initially explored for antifungal and cytotoxic effects, its primary application became immunosuppression to prevent transplant rejection.
• Early studies suggested lower nephrotoxicity compared to calcineurin inhibitors (CNIs), though later findings indicated potential kidney function detriments.

Purpose of the Study:

• To review the evolving role and multifaceted effects of rapamycin in organ transplantation.
• To explore rapamycin's potential in mitigating fibrotic processes and promoting immunological tolerance post-transplant.
• To highlight rapamycin's anticancer activities due to its role in tumor development pathways.

Main Methods:

• Literature review of rapamycin's historical and current applications in organ transplantation.
• Analysis of studies investigating rapamycin's impact on immunosuppression, nephrotoxicity, and fibrotic processes.
• Examination of research on the mTOR pathway's involvement in cancer and rapamycin's potential anti-tumor effects.

Main Results:

• Rapamycin's immunosuppressive properties have been pivotal in reducing transplant rejection.
• Evidence suggests rapamycin can interfere with fibrotic processes and promote immune tolerance.
• Rapamycin exhibits anticancer activities by targeting key tumor development pathways like angiogenesis and cell growth.

Conclusions:

• Rapamycin's utility in organ transplantation is multifaceted, extending beyond immunosuppression.
• Its potential to combat fibrosis, enhance tolerance, and fight cancer in transplant recipients warrants further investigation.
• The full therapeutic value of rapamycin in transplantation is still under exploration.